Comparative Pharmacology
Head-to-head clinical analysis: AMERGE versus SUMAVEL DOSEPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMERGE versus SUMAVEL DOSEPRO.
AMERGE vs SUMAVEL DOSEPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; binds to 5-HT1B and 5-HT1D receptors on cranial blood vessels and trigeminal nerve endings, causing vasoconstriction and inhibition of pro-inflammatory neuropeptide release.
Sumatriptan is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, causing vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission.
2.5 mg orally at onset of migraine; may repeat after 4 hours if needed, maximum 5 mg in 24 hours.
Sumavel DosePro (sumatriptan injection) is administered subcutaneously via a single-use needle-free injector. The typical adult dose is 6 mg subcutaneously once, with a maximum of 6 mg per 24 hours. A second injection may be given at least 1 hour after the first if symptoms recur, but not more than two injections in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 13-40 hours). This long half-life allows for once-daily dosing for prophylaxis, but may prolong the duration of adverse effects.
Terminal elimination half-life is 2.5–3 hours. Clinical context: Short half-life allows titrated dosing; may prolong in hepatic impairment.
Renal excretion accounts for approximately 50% of the dose, with about 40% as unchanged drug and 10% as metabolites. Fecal excretion accounts for 30% of the dose. The remainder is unknown.
Primarily renal (60% unchanged, 20% as indole acetic acid metabolite) and fecal (about 10%). Biliary excretion contributes minimally.
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine